Torrent Pharma recalls select batches of Semalix injection

Torrent Pharmaceuticals said it is voluntarily recalling select batches of its Semalix injection disposable pens as a precautionary measure after a notice from Dr. Reddy's tied to semaglutide batch quality issues.

Semalix is used for diabetes treatment. Torrent did not disclose the specific batch numbers or geographies covered by the recall in the information available so far.

Why the recall happened

The move follows a separate disclosure from Dr. Reddy's Laboratories, which said commercial supplies of its semaglutide product would be delayed after certain batches were found out of specification.

Dr. Reddy's said the issue was linked to the active pharmaceutical ingredient used in the drug. The company did not publicly identify a broader defect beyond the out-of-specification batches in the material reviewed.

What is known so far

The available reporting indicates that Torrent's recall is precautionary and limited to select batches. No regulator guidance or official batch list was included in the information reviewed for this story.

The development matters because semaglutide is a fast-growing diabetes drug class in India, and the issue could affect supply confidence for newly launched products.

What to watch next

Key follow-up questions are whether Torrent or Dr. Reddy's names specific batch numbers, whether any regulators issue public instructions, and whether the recall expands to other markets or additional semaglutide products.

Further company filings or recall notices may clarify the scope, the underlying quality concern and whether the supply disruption spreads beyond the batches already identified.